Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The voltage-gated sodium channel protein type II alpha subunit, commonly abbreviated as Nav1.2, is a critical membrane protein in humans encoded by the SCN2A gene. It forms the core of a voltage-gated sodium channel complex that is essential for the initiation and propagation of action potentials in neurons. Mutations or dysfunctions in SCN2A/Nav1.2 are associated with several neurological disorders. Nav channels are targets for various drugs including local anesthetics, anticonvulsants, antiarrhythmics, as well as toxins from marine organisms that affect gating or conductance properties.
Various drugs affect gating or conductance properties of Nav1.2. Beta subunits influence channel kinetics.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Voltage-Gated Sodium Channel Protein Type II Alpha Subunit (Nav1.2).